POPULAR CLASS OF A DIABETIC DRUG DECREASES GLAUCOMA RISK

 In this study,  type 2 diabetic patients taking Glucagon-like Peptide-1 Receptor Agonist (GLP-1RAs) have an initial 19% reduced glaucoma risk, increasing to a 29% reduction after 3 years.   

Examples of GLP-1RAs include Exanatide (Byetta), Semaglutide (Ozempic), Liraglutide (Victoza, Saxenda), and Lixisenatide (Adlyxin).  



Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH